Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens
Emanuel Gonçalves(European Bioinformatics Institute), Mathew J. Garnett(Wellcome Sanger Institute), James T. Lynch(AstraZeneca (United Kingdom)), James Morris(North Carolina State University), Charlotte Tolley(Wellcome Sanger Institute), Elizabeth A. Coker(Wellcome Sanger Institute), Andrew R. Leach(LifeArc), Gabriele Picco(Wellcome Sanger Institute), Alexandra Beck(Wellcome Sanger Institute), Laura Richardson(Wellcome Sanger Institute), Fiona M. Behan(Age UK), Patricia Jaaks(Wellcome Sanger Institute), Clare Pacini(Wellcome Sanger Institute), Claire Crafter(AstraZeneca (United Kingdom)), Aldo Segura‐Cabrera(European Bioinformatics Institute), Caitlin Hall(Wellcome Sanger Institute), Howard Lightfoot(Wellcome Sanger Institute), Frances Thomas(Wellcome Sanger Institute), Wanjuan Yang(Wellcome Sanger Institute), Ben Sidders(AstraZeneca (United Kingdom)), Tatiana Mironenko(Wellcome Sanger Institute), Ermira Lleshi(Wellcome Sanger Institute), Francesco Iorio(Human Technopole), Stephen E. Fawell(AstraZeneca (United States)), Iman Mali(Wellcome Sanger Institute), James Hall(Wellcome Sanger Institute), Andrew Barthorpe(Wellcome Sanger Institute)
Cited by 115
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
|Journal of Molecular Biology|1997|6.7k
Drug repurposing: progress, challenges and recommendations
|Nature Reviews Drug Discovery|2018|4.6k
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k